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Background/Aims: Ghrelin agonists are emerging proki-
netic agents for treating gastroparesis. Although recent clini-
cal trials have demonstrated their efficacy in patients with 
diabetic gastroparesis (DG), the impact of such agents on 
symptoms and gastric dysmotility remains unclear. We per-
formed a systematic review and meta-analysis to evaluate 
the efficacy and safety of ghrelin agonists in patients with 
DG. Methods: A search of common electronic databases 
(MEDLINE, Embase, and Cochrane Central Register of Con-
trolled Trials) was preformed, using keyword combinations 
that referenced ghrelin and DG and retrieving all eligible ran-
domized controlled trials (RCTs) of ghrelin agonists versus 
placebo in patients with DG. The primary outcome measure 
was the change in patient-reported overall gastroparesis 
symptom scores. Secondary outcomes included the change 
in gastric emptying time, specific symptoms related to gas-
troparesis, and adverse events. A random-effects model was 
applied to all study outcomes. Heterogeneity among stud-
ies was determined by the chi-square test and I2 statistics. 
Results: We selected six RCTs of patients with DG (n=557) 
for meta-analysis. Ghrelin agonist administration (vs pla-
cebo) significantly improved overall gastroparesis symptoms 
(standardized mean difference, –0.34; 95% confidence 
interval, –0.56 to –0.13) and significantly improved symp-
toms related to gastroparesis, including nausea, vomiting, 
early satiety, and abdominal pain. Adverse events recorded 
for ghrelin agonists and placebo did not differ significantly. 
There was no significant heterogeneity among eligible stud-
ies. Conclusions: Compared with placebo, ghrelin agonists 
are effective and well-tolerated for the treatment of DG. (Gut 
Liver 2020;14:589-600)
Key Words: Diabetes mellitus; Gastroparesis; Ghrelin; Meta-
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INTRODUCTION
Diabetic gastroparesis (DG) is a serious complication of long-
standing diabetes mellitus, resulting in malnutrition, poor gly-
cemic control, and poor quality of life.1,2 In a U.S. population-
based study, 10-year cumulative incidences of DG for patients 
with type 1 and 2 diabetes mellitus were 5.2% and 1.0%, re-
spectively; and the risk of DG was >30-fold in those with type 
1 diabetes mellitus, relative to age-/sex-matched controls.3 Al-
though various prokinetic agents, namely dopamine D2 receptor 
antagonists (metoclopramide and domperidone) and motilin 
receptor agonists (erythromycin), are current mainstays in the 
treatment of DG,4,5 their long-term use is hampered by adverse 
events (AEs) (i.e., potential tardive dyskinesia) or waning ef-
ficacy due to tachyphylaxis.4 Consequently, novel agents with 
differing mechanisms of action must be developed to ensure 
long-term efficacy and safety in the treatment of DG.
Ghrelin is a peptide hormone released from gastric mucosal 
endocrine cells that serves as a ligand for growth hormone 
secretagogue receptor 1a.6 In vitro studies have shown the 
expression of ghrelin receptor in enteral nervous system of hu-
man and animal intestine.7,8 Preclinical studies have shown that 
ghrelin enhances gastrointestinal (GI) motility via stimulation of 
vagal signaling, thus prompting efforts at therapeutic targeting.6 
Ghrelin can also affect GI motility directly within the enteric 
nerve system or within the central nerve system via crossing the 
blood-brain barrier.6 The prokinetic effects of ghrelin on GI mo-
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tility have been demonstrated in postsurgical, opioid-induced as 
well as diabetic models of rodents with various routes of admin-
istration.9
Synthetic selective ghrelin receptor agonists, including TZP-
101 (ulimorelin), TZP-102, and RM-131 (relamorelin), are under 
development and actually surpass native ghrelin in half-life.10,11 
TZP-101 is a first-in-class ghrelin agonist with a potent binding 
affinity for ghrelin receptor.12 In the first phase I human study 
of ghrelin agonists, parenteral TZP-101 was well tolerated with 
a promising pharmacokinetic and pharmacodynamic profile for 
use in healthy volunteers.11 The volume of distribution is ap-
proximately 114 mL/kg and half-life values of approximately 
13 hours, which were independent of dose.11 However, several 
prospective randomized controlled trials (RCTs) showed inconsis-
tent efficacy of ghrelin agonists for the treatment of DG.13-18 In a 
phase 2b, randomized, double-blind 12-week placebo-controlled 
trial, oral TZP-102 was not superior to placebo for the treatment 
of DG, but there was substantial improvement of symptoms in 
both ghrelin agonist and placebo groups.15 In a recent phase 2b 
randomized, placebo-controlled trial among the largest number 
of patients with moderate to severe gastroparesis symptoms 
related to diabetes, RM-131 significantly reduced gastroparesis 
symptoms compared to placebo with acceleration of gastric 
emptying.18 Therefore, we conducted this systematic review and 
meta-analysis to better assess the efficacy and safety of syn-
thetic ghrelin agonists (compared with placebo) in the treatment 
of DG. 
MATERIALS AND METHODS
This systematic review and meta-analysis were conducted in 
accord with Preferred Reporting Items for Systematic and Meta-
analysis (PRISMA) report guidelines.19
1. Search strategy and study selection
Using common electronic databases (MEDLINE, Embase, and 
Cochrane Central Register of Controlled Trials), we searched the 
medical literature (prior to June 2018) for the following terms: 
ghrelin AND (diabetic OR diabetes) AND (gastroparesis OR gas-
tropathy). Two independent authors (S.W.H. and J.K.) reviewed 
and selected pertinent studies, all restricted to English language. 
Eligible publications met the following criteria: (1) any patient 
with DG; (2) ghrelin agonist intervention; (3) placebo as com-
parator; (4) gastroparesis symptoms, gastric emptying time (GET), 
and AEs as outcomes; and (5) prospective comparative study 
design (Supplementary Material 1). There were no restrictions 
on drug regimens or durations of treatment. Abstracts, case re-
ports, review articles, non-comparative studies, and preclinical 
studies were excluded from this meta-analysis. 
2. Data extraction and quality assessment
Two authors (S.W.H. and J.K.) independently extracted data 
from eligible studies, resolving any disagreement by consensus. 
Extracted data included the following: named author(s); trial lo-
































10 Full-text articles assessed
for eligibility
6 Studies included in
qualitative synthesis
6 Studies included in quantitative
synthesis (meta-analysis)
341 Records excluded after
review of titles and abstracts
80 Records identified through
PubMed database searching
4 Full-text articles excluded,
with reasons
2 No numeric data
1 Subset data of other study
1 Data unavailable of
quantitative analysis
330 Records identified through
Embase database searching
30 Records identified through
Cochrane database searching
Fig. 1. Flowchart of meta-analysis study selection.
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ment; number of enrollees in each treatment arm; posttreatment 
change in DG symptom scores and scale applied in symptom 
assessment; change in GET and method of measurement; and 
AEs. In dose-dependent RCTs, the regimen with the greatest 
clinical efficacy in terms of the change in overall gastroparesis 
symptoms was preferred for extracting data (Supplementary 
Table 1). In studies with varying assessment scales, data related 
to primary outcome measures were chiefly extracted. We also 
contacted corresponding authors to clarify or remedy confusing 
or missing information. The risk of bias tool of the Cochrane 
Group served to gauge quality of analysis.20
3. Study outcomes and measurement scales
The primary outcome measure was change in severity of 
overall gastroparesis symptoms, based on patient-reported 
scales. Secondary outcomes were change in GET, specific 
gastroparesis-related symptoms gauged before and after treat-
ment, and AEs. There are a variety of patient-reported scales for 
measuring symptoms related to gastroparesis. The Gastroparesis 
Cardinal Symptom Index (GCSI)21 and Patient Assessment of 
Upper Gastrointestinal Symptom Severity Index (PAGI-SYM) 
have been widely used.22 Recently, GCSI was revised as a daily 
diary,23 and the Diabetic Gastroparesis Symptom Severity Diary 
(DGSSD) was also developed to score symptoms of DG. In this 
regard, we made no restrictions on patient-reported scales when 
selecting study outcomes for meta-analysis. GET was equated 
with gastric emptying half-time after ingesting an isotope-la-
beled diet. A breath test or scintigraphy served to measure half-
times of gastric emptying. Data on GET were likewise extracted 
without regard to measurement methods. We also extracted 
data on AEs and serious adverse events (SAEs), based on results 
presented in each study, detailing events and numbers of pa-
tients affected.
4. Statistical methods
Dichotomous outcomes were calculated as odds ratios (ORs), 
with 95% confidence intervals (CIs). Continuous data were each 
expressed as standardized mean difference (SMD) or mean dif-
ference (MD), with 95% CI. Given the diversity in scoring of 
gastroparesis symptoms, we used SMD to report pooled treat-
ment effects, whereas results of same-scale GET analytics were 
expressed as MDs. A random-effects model was ultimately 
invoked, applying inverse-variance method for all study out-
comes. Some data proved insufficient to calculate standard 
deviations of changes occurring, so we imputed values (cor-
relation coefficients) derived from other studies.20 A p<0.05 was 
considered statistically significant. Heterogeneity among studies 
was estimated via chi-square test and I2 statistics. Significance 
in chi-square testing was set at p<0.10, gauging heterogeneity 
among studies by I2 statistics as follows: 0% to 40%, marginal; 
30% to 60%, moderate; 50% to 90%, substantial; and 75% to 
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Table 2. Regimen and Treatment Duration of Ghrelin Agonists in Each Study
Author Medication name Regimen Selected regimen for analysis Treatment duration
Ejskjaer et al.13 TPZ-101* 20, 40, 80 160, 320, and 600 µg/kg
   single daily IV infusion
80 µg/kg single 
   daily infusion
  4 Days
Ejskjaer et al.14 TPZ-102 10, 20, and 40 mg qd p.o. 20 mg qd p.o. 28 Days
McCallum et al.15 TPZ-102 10, 20 mg qd p.o., 10 mg tid p.o. 10 mg qd p.o. 12 Weeks
Shin et al.16 RM-131† 100 µg qd s.c. 100 µg qd s.c.   1 Days
Lembo et al.17 RM-131 10 µg qd, bid s.c. 10 µg bid s.c. 28 Days
Camilleri et al.18 RM-131 10, 30, and 100 µg bid s.c. 100 µg bid s.c. 12 Weeks
IV, intravenous; qd, once daily; p.o., per oral; tid, three times daily; s.c., subcutaneous; bid, twice daily.
*TPZ101 referred to as ulimorelin; †RM-131 referred to as relamorelin. 
Fig. 2. Efficacy of ghrelin agonists (vs placebo) for treating gastroparesis symptoms overall: (A) subgroup analysis by agent (TZP-101, 102, or RM-
131), (B) subgroup analysis by route of administration (parenteral vs oral), and (C) subgroup analysis by treatment duration.
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heterogeneity and conducted subgroup analyses according to 
type of ghrelin agonists, route of administration and treatment 
duration. All computations relied on Review Manager freeware 
(RevMan v5.3; Cochrane Community, London, UK).
RESULTS
1. Search selection
Our literature search returned a total of 438 articles. Dis-
counting duplicates, 351 articles remained for title and abstract 
screening. The latter yielded 10 articles for full text assessment, 
but only six met our inclusion criteria and advanced to data 
extraction/synthesis (Fig. 1).13-18 A study by Shin et al.24 fulfilled 
the conditions for enrollment in this meta-analysis, but the val-
ues were only presented with median and interquartile range. 
The values with median and interquartile range could not be 
converted to those with mean and standard deviation in the 
absence of raw data. Hence, the study was excluded from the 
qualitative synthesis stage.
2. Study characteristics and risk of bias assessment
All publications selected for analysis (n=557) were prospec-
tive RCTs. Each subject with DG had been stratified to test agent 
(n=263) or placebo (n=294) groups. Five studies were parallel 
investigations,13-15,17,18 and the remaining trial was a cross-over 
study.16 Four were multinational efforts,13-15,18 and two were 
conducted in the United States.16,17 Patient-reported scales for 
assessment of gastroparesis symptoms were distributed as fol-
lows: GCSI, three RCTs;13-15 GCSI daily diary, four RCTs;15-18 
PAGI-SYM, three RCTs;14,15,17 and DGSSD, two RCTs (Table 1).17,18 
In all study populations, prolongation of GET was stipulated in 
screening phases of those studies eligible for meta-analysis, five 
of them designating change in GET as a study outcome.14-18 With 
exception of one RCT (using scintigraphy), GET was determined 
by breath test.16 Characteristics and study outcomes of RCTs se-
lected for meta-analysis are summarized in Table 1.
These studies differed in terms of drugs used, dosages, methods 
of administration, and treatment durations (Table 2). One study 
was aimed at TZP-101,13 another two tested TZP-102,14,15 and 
the final three evaluated RM-131,16-18 showing wide variation 
in duration of treatment (range, 1 day to 12 weeks). The report 
of McCallum et al.15 provided results of two clinical trials with 
different dosing schedules (once daily and three times daily). Be-
cause the researchers allowed dual enrollment, we selected one 
of the regimens by the selection criteria according to the greatest 
clinical efficacy on overall gastroparesis symptoms.15
The risk of bias is shown in Supplementary Figs 1 and 2. 
Methods of randomization and allocation concealment were 
clearly detailed in all studies having low risks of performance 
and detection bias, except the study by Lembo et al.17 with in-
sufficient information on the risk of allocation concealment. 
Attrition rates in two RCTs were high.17,18
3. Overall gastroparesis symptoms
Our meta-analysis confirmed a significantly better perfor-
mance by ghrelin agonists (vs placebo) regarding change in 
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overall gastroparesis symptoms scores (SMD, –0.34; 95% CI, 
–0.56 to –0.13). There was no significant heterogeneity among 
studies (p=0.26; I2=23%). RM-131 differed significantly, com-
pared with placebo (SMD, –0.29; 95% CI, –0.54 to –0.05), and 
so did TZP-101,102 (SMD, –0.49; 95% CI, –0.94 to –0.04). Ghre-
lin agonist via parenteral route differed significantly, compared 
with placebo (SMD, –0.35; 95% CI, –0.64 to –0.07), although 
orally administered ghrelin agonist did not (SMD, –0.37; 95% 
CI, –0.88 to 0.13). The efficacy of ghrelin agonists for improv-
ing overall gastroparesis symptoms was only found at 12-week 
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Fig. 3. Efficacies of ghrelin agonists (vs placebo) in treating specific gastroparesis symptoms: (A) nausea, (B) vomiting, (C) early satiety, (D) bloat-
ing, and (E) abdominal pain.
Std., standardized; IV, inverse variance; CI, confidence interval.
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4. Specific gastroparesis symptoms
Ghrelin agonists (vs placebo) significantly improved nausea 
(SMD, –0.38; 95% CI, –0.64 to –0.13), vomiting (SMD, –0.44; 
95% CI, –0.72 to –0.16), early satiety (SMD, –0.34; 95% CI, –0.58 
to –0.10) and abdominal pain (SMD, –0.33; 95% CI, –0.52 to 
–0.15). However, bloating was not improved by ghrelin agonist 
(i.e., similar to placebo) (Fig. 3). 
5. Gastric emptying time
In a study by Shin et al.,16 there were no available data on 
GET at baseline, even upon contacting authors for informa-
tion. This study was subsequently excluded from meta-analysis. 
Ghrelin agonists showed a tendency to improve GET compared 
with placebo (MD, –8.04; 95% CI, –17.17 to 1.08). RM-131 
(parenteral) significantly shortened GET, compared with placebo 
(MD, –14:52; 95% CI, –23.48 to –5.57), but TZP-102 (oral) did 
not (Fig. 4).
6. Adverse events
The pooled effects of AEs were based on the number of pa-
tients with AEs in all eligible studies, regardless of dosing regi-
men. The proportion of patients with AEs or SAEs in each study 
and the relevance to treatment were summarized in Table 3. 
Accordingly, no significant difference between ghrelin agonist 
and placebo was evident (OR, 1.33; 95% CI, 0.71 to 2.48). Simi-
larly, there was no significant difference in pooled SAEs (OR, 
1.00; 95% CI, 0.54 to 1.83) (Fig. 5). AEs common to each ghrelin 
agonist were GI symptoms, such as nausea, vomiting, diarrhea, 
and abdominal pain. AEs related to glycemic control were also 
frequently reported. SAEs were rare, including coronary heart 
disease, atrial fibrillation, diabetic ketoacidosis, and serious infec-
tious (i.e., pneumonia, urinary tract infection, and sepsis). Most 
studies under investigation did not clearly document associa-
tions between ghrelin agonists and AEs, and no definitive dose-
response relations were discerned. Although AEs linked to hyper-
glycemia were not significantly increased, blood glucose trended 
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Fig. 4. Effects of ghrelin agonists (vs placebo) on gastric emptying time.
IV, inverse variance; CI, confidence interval.
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study by Camilleri et al.,18 some recipients of RM-131 displayed 
dose-dependent glycemic increases.
DISCUSSION
This meta-analysis is seemingly the first to evaluate the ef-
ficacy and safety of ghrelin agonists (vs placebo) in the treat-
ment of DG. We found that such agents significantly improve 
overall gastroparesis symptoms and show a tendency to reduce 
GET. Although the relation between symptom improvement and 
GET is still controversial, both parameters are current standard 
outcome measures of drugs used to treat gastroparesis.25 Hence, 
our data support the therapeutic potential of ghrelin agonists in 
managing patients with DG. 
Although all types of ghrelin agonists significantly outper-
formed placebo in patients with DG in terms of improving 
overall DG symptoms, there was a significant difference of the 
effects on GET between parenteral RM-131 and oral TZP-102. 
Preclinical data on RM-131 indicates a much greater potency 
(600- to 1,800-fold) for ghrelin receptors than TZP-102, offer-
ing a plausible explanation for the differing efficacy observed in 
patients with DG.10 Among the 3 studies using RM-131 on the 
treatment of patients with DG, only study by Camilleri et al.18 
reported the significant efficacy of RM-131 on improvement of 
overall gastroparesis symptoms following the long-term admin-
istration of the highest dose (100 µg twice daily for 12 weeks), 
compared to placebo. Therefore, various dosage and treatment 
duration of RM-131 may affect the inconsistent results among 
the studies. However, the route of administration might also be 
related to the efficacy of ghrelin agonists. Compared with oral 
TZP-102 intake for more than 4 weeks, short-term parenteral 
administration of TZP-101 brought significantly greater im-
provement in overall symptoms. Unfortunately, there is no pub-
lished data as yet on the bioavailability of orally administered 
ghrelin agonists, and our preliminary evidence is inconclusive. 
As further validation, oral formulations of ghrelin agonists more 
potent than TZP-102 must be evaluated in patients with DG. 
In terms of specific DG-related GI symptoms, ghrelin agonists 
significantly improved abdominal pain, nausea, early satiety 
and vomiting, but not bloating. Although the pathophysiology 
of symptoms related to DG remains elusive,26 various sources 
maintain that chief etiologic factors of given GI symptoms may 
differ as follows: (1) visceral hypersensitivity to gastric disten-
sion leads to epigastric pain; (2) delayed gastric emptying results 
in postprandial fullness, nausea, and vomiting; and (3) impaired 
accommodation promotes early satiety.27-30 Thus, the differing 
efficacies displayed in these trials for each symptom of DG are 
explainable. To date, the major role defined for ghrelin agonists 
is an enhancement of GI motility via vagal stimulation.6 The 
ghrelin infusion reduced gastric accommodation in the clinical 
trial for healthy volunteers and at least one preclinical study 
suggests that ghrelin has antinociceptive effects, which counter 
Fig. 5. Ghrelin agonist and placebo group comparison: (A) adverse events and (B) serious adverse events.
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visceral hypersensitivity.31,32 Indeed, ghrelin agonists act to re-
duce GET, visceral hypersensitivity and gastric accommodation, 
thereby improving nausea, vomiting, early satiety, and abdomi-
nal pain. On the other hand, bloating may be a heterogeneous 
condition involving multiple pathophysiologic factors.33 Con-
sequently ghrelin agonists may offer no benefits for bloating 
related to DG.
One of the major concerns when using ghrelin agonists is the 
adverse effect on glycemic control. Tight glycemic control is 
paramount in patients with DG, so it is essential to address this 
issue.4 Earlier efforts have shown that the infusion of ghrelin 
agonists increases plasma growth hormone concentration, thus 
opposing the action of insulin.34,35 In a literature review, how-
ever, strong evidence of significant blood glucose elevations 
due to ghrelin agonists was lacking in patients with DG.24,34-36 
Herein, the risk of AEs related to hyperglycemia only trended 
higher in our ghrelin agonist group, failing to dispel such fears. 
Additional prospective studies are needed to clarify this aspect 
of long-term ghrelin agonist use and other related complica-
tions.
This study has several acknowledged limitations. Although 
significant improvement was shown at the 12-week treatment 
duration, the efficacy of ghrelin agonists for improving overall 
gastroparesis symptoms could not be fully evaluated based on 
treatment duration due to lack of studies enrolled in this meta-
analysis. The long-term efficacy of ghrelin agonists in manag-
ing DG could not be ascertained as well, because the maximum 
study period among studies included was a mere 12 weeks. In 
addition, there was no data on the enduring efficacy of these 
agents after their withdrawal. Another weakness is that the rare 
AEs of ghrelin agonists in the setting of DG could not be prop-
erly assessed in the small number of available patients. There 
is concern that ghrelin agonist may heighten cancer risks due 
to the carcinogenic effects of growth hormone.37 Although in 
vivo study findings indicate that serum ghrelin level has a null 
or inverse association with cancer risks,38 the role of ghrelin/
ghrelin agonists in the development and progression of cancer 
is still in doubt. Ultimately, large-scale clinical studies will be 
needed to evaluate the long-term efficacy and safety profile 
of ghrelin agonists during treatment of DG. Finally, it remains 
elusive whether the inconsistent results regarding the efficacy of 
ghrelin agonists on overall symptoms related to DG were due to 
administration route or dosage. The efficacy of ghrelin agonists 
for the treatment of DG may be valid only for specific regimen 
although overall efficacy of ghrelin agonists for improvement 
of gastroparesis symptoms in the meta-analysis. Further studies 
are required to determine oral bioavailability and comparative 
efficacy of ghrelin agonists between drug types in patients with 
DG.
In conclusion, ghrelin agonists effectively improve symptoms 
related to gastroparesis in patients with DG, more so than pla-
cebo. Despite concerns over blood glucose levels during long-
term ghrelin agonist use, no significant treatment-related safety 
issues emerged in the course of this meta-analysis. 
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